Pathological Response After Neoadjuvant Treatment on NSCLC
Retrospective Observational Study of Resectable Stage IIIA Non-small Cell Lung Cancer Patients: Pathological Response After Neoadjuvant Treatment and Patient Outcomes
Fundación GECP
150 participants
Dec 13, 2021
OBSERVATIONAL
Conditions
Summary
This is a non-interventional, observational, multicenter and retrospective study. Being limited to the collection of patient data already filled in the Tumor Thoracic Registry data base and the data from stage IIIA clinical trials case report forms.
Eligibility
Inclusion Criteria6
- Patients with resectable stage IIIA disease (according to American Joint Committee on Cancer \[AJCC\] lung cancer edition 7 or 8) who were included in the Tumor Thoracic Registry data base and in stage IIIA clinical trials which the sponsor is Fundación GECP.
- Patients with histologically N2 involvement confirmed
- Patients diagnosed as stage IIIA from 2010 and 2017
- Patients who have received neoadjuvant platinum-based treatment and surgery
- Age ≥ 18 years at time of study entry
- PET /TC at diagnosis
Exclusion Criteria3
- Patients who received chemoradiotherapy neoadjuvant treatment
- Patients who were not resected after neoadjuvant treatment
- Patients who were diagnosed after June 2017
Interventions
Route of administration: Intravenous infusion. Neoadjuvant chemotherapy is often given 2 to 4 months before surgery.
Route of administration: Intravenous infusion. Neoadjuvant chemotherapy is often given 2 to 4 months before surgery.
Locations(17)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05167487